A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis (Q42651835)

4 November 2017

A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis (English)

1 reference

secondary progressive multiple sclerosis

4 November 2017

0 references

multiple sclerosis

0 references

author name string

Jonathan E Walker

series ordinal

1

1 reference

PubMed ID

15794387

4 November 2017

Shri N Giri

series ordinal

2

1 reference

PubMed ID

15794387

4 November 2017

Solomon B Margolin

series ordinal

3

1 reference

4 November 2017

1 April 2005

1 reference

Multiple Sclerosis Journal

4 November 2017

1 reference

4 November 2017

11

1 reference

4 November 2017

2

1 reference

4 November 2017

149-158

1 reference

Revised estimate of the prevalence of multiple sclerosis in the united states

4 November 2017

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Genetic epidemiology of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Cytokines in inflammatory brain lesions: helpful and harmful

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Tumor necrosis factor identified in multiple sclerosis brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression in primary cultures of human brain microvessel endothelial cells by cytokines and lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Cytokine-induced expression of intercellular adhesion molecule-1 (ICAM-1) in cultured human oligodendrocytes and astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Nitric oxide, a novel biologic messenger

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Nitric oxide: foe or friend to the injured brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Evidence for increased lipid peroxidation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

The clinico-radiological paradox in multiple sclerosis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

The emerging role of MRI in multiple sclerosis and the new diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Macrophage and microglial responses to cytokines in vitro: phagocytic activity, proteolytic enzyme release, and free radical production

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

TNF, apoptosis and autoimmunity: a common thread?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Function and activation of NF-kappa B in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Effects of oxidants and antioxidants on nuclear factor kappa B activation in three different cell lines: evidence against a universal hypothesis involving oxygen radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1134OA

10.1191/1352458505MS1134OA

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference

PubMed ID

15794387